Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DermaMatrix is an acellular dermal matrix (ADM) derived from human cadaveric dermis. It is processed to remove all viable cells and immunogenic components, leaving behind a collagen-rich extracellular matrix scaffold. This structure supports tissue regeneration by allowing host cells—including fibroblasts, myofibroblasts, lymphocytes, and others—to infiltrate the matrix, promoting organized tissue repair and revascularization. DermaMatrix is primarily used in reconstructive surgery (such as breast reconstruction post-mastectomy), wound healing (including chronic wounds, burns, ulcers), abdominal wall reconstruction (hernia repair), periodontal/dental surgery for soft tissue augmentation, and orthopedic/tendon repairs. Its biocompatibility reduces the risk of rejection or inflammatory response while providing a stable framework for new tissue growth[5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DermaMatrix.